ages for pneumococcal
Women constitute most of. the adult U.S. population >50 years of age (60% of those. 75 years of age and 70% of those 85 years of age). The immune system does not function as well with. advancing age (5). For example, T-cell functions diminish. with age, as evidenced by the increased prevalence of. Because ≈30% of the U.S. population 50–64. years of age have one or more conditions that warrant. influenza vaccination (1) and because age-based recom-. mendations are easier to implement, 50 years of age has. now been established as the time for beginning the univer-. sal annual influenza vaccination (13). 0 3. 3 doses, all administered before age 12. months. 1 4. 4 doses 0 4. * Recommended vaccine schedule for children starting the series on time is at 2 months, 4 months, 6 months, and 12-15 months of age. Minimum age for administration of first dose is. 6 weeks. PPSV23 (Pneumovax, Merck) is recommended. for anyone who meets any of the criteria below: • Age 65 years and older. • age 59 months and give PCV13 to children Age 2 through 64 years with any of the fol-. lowing conditions. 1. cigarette smokers age 19 years and older. 2. alcoholism. 3. chronic liver disease, cirrhosis. Children younger. than age 5 and adults older than 65 have the. highest incidence of serious disease. Case-fatality rates are highest for pneumo-. coccal meningitis and bacteremia, and the. highest mortality occurs among the elderly and. patients who have underlying medical condi-. PNEUMOVAX®23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F). For persons age 65 years and older who have. not previously received pneumococcal vac-. cine or whose pneumococcal vaccine history. is unknown, give PCV13 followed by PPSV23. 12 months later. For adults 19 through. 64 years at high risk of pneumococcal dis-. PNEUMOVAX 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease. PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. The 13-valent pneumococcal conjugate vaccine (PCV13) is recommended for all children aged <5 years and children aged <72 months with chronic medical conditions; the vaccine is also recommended for children aged <18 years with immunocompromising conditions. The most common adverse reactions, reported in >10% of subjects vaccinated with PNEUMOVAX 23 in clinical trials, were: injection-site pain/soreness/tenderness, injection-site swelling/induration, headache, injection-site erythema, asthenia and fatigue, and myalgia.
65 years